Piramal Pharma Solutions Reports Milestone in Global Regulatory Compliance

The Mumbai-based CDMO attributes these results to an aggressive, long-range strategy that prioritizes sustained compliance over periodic checks. By integrating predictive quality tools and digital platforms like eLab and exForms, the company has replaced manual oversight with systems designed to improve efficiency and reduce the cost of poor quality. A core component of this transition is the RESOLVE program, which emphasizes right-first-time execution in manufacturing and quality control labs through concurrent batch record review and site-wide quality ownership.

Technological investments are playing a central role in this evolution. The adoption of iAssist, a human-in-the-loop AI tool, has enabled teams to structure investigation outputs more consistently while reducing manual labor. According to Chief Quality Officer Rashida Najmi, the objective is to weave quality into everyday operations, ensuring that audit readiness becomes an inherent state rather than an episodic event. This discipline supports the company’s extensive service portfolio, which spans drug discovery, clinical trial supplies, and commercial API production across its facilities in North America, Europe, and Asia.